Table 1.

Demographic and risk factor characteristics of patients and controls for the acquisition of C. glabrata

CharacteristicPatients with newly acquired C. glabrata (n = 16)All patients infected or colonized with C. glabrata (n = 24)Patients not infected or colonized withCandida species (n = 33)
Mean age (yr [range])45.9 (19–88)47.0 (19–88)49.1 (5–85)
Sex (no. of males/no. of females)3/134/2020/11
Mean duration in unit (days)18.817.67.6a
Mean duration in study (days [range])35.6 (7–89)33.0 (7–89)39.1 (4–101)
No. (%) of patients with prior antibiotic therapy16 (100)16 (67)20 (65)a
No. (%) of patients with prior antifungal therapy8 (50)8 (33)16 (52)
No. of patients receiving prior systemic antifungal therapy7 (3 flz)b 7 (3 flz)7 (2 flz)
No. (%) of patients receiving immunosuppressive therapy10 (63)15 (63)23 (74)
No. (%) of patients with granulocytopenia9 (56)13 (54)14 (45)
No. (%) of patients with the following underlying illness:
 Malignancy11 (67)16 (66)21 (68)
 Cardiac disease2 (13)2 (8)6 (19)
 Neurologic disease1 (6)1 (4)5 (16)
  • a P < 0.001; significant in multivariate analysis.

  • b Values in parentheses are numbers of patients receiving fluconazole (flz).